MAGED1 and breast cancer: These data are supported by a previous study showing that ZNF350 and MAGED1 were hyper-methylated in tamoxifen-resistant breast cancer cell lines, and treatment with 5-aza-2′deoxycytidine caused a significant reduction in promoter methylation of both genes [38].